Efficacy News and Research

RSS
Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Early onset of dietary treatment may slow down progression of Alzheimer's, says research

Early onset of dietary treatment may slow down progression of Alzheimer's, says research

Study suggests potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth

Study suggests potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth

Scientists map genetic changes that drive tumors pediatric soft-tissue cancer

Scientists map genetic changes that drive tumors pediatric soft-tissue cancer

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Social cognitive deficits contribute to perpetuation of cocaine addiction, say scientists

Social cognitive deficits contribute to perpetuation of cocaine addiction, say scientists

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Dihydroartemisinin-piperaquine more effective than artemether-lumefantrine in treating malaria

Dihydroartemisinin-piperaquine more effective than artemether-lumefantrine in treating malaria

Daytime water restriction effective in nocturia

Daytime water restriction effective in nocturia

Technology increases cognitive behavioral therapy options for insomnia

Technology increases cognitive behavioral therapy options for insomnia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.